Fatty liver disease linked to diabetes and obesity can easily progress to liver cirrhosis, but new research suggests that GLP ...

Ashkenazi was CFO at Lilly from 2021 until leaving the company this summer. Like Montarce, she joined Lilly in 2001. During ...

On Friday, the U.S. Food and Drug Administration approved Eli Lilly's eczema drug for use in adults and children 12 and older ...

The maker of blockbuster appetite-suppressing drugs Mounjaro and Zepbound is seeking to end a regulatory designation that has ...

At "science day" in a Philly courthouse, both sides of a potentially ground-shifting legal case discussed how the diabetes ...

Novo Nordisk CEO Lars Jørgensen will testify about the high cost of Ozempic and Wegovy at an upcoming HELP Committee hearing on September 24th.

A recent announcement by Eli Lilly suggests that the company understands the economic conundrum some patients face. Per a ...

The race is on to develop the first daily weight-loss pill that would be both cheaper and less invasive than the current ...

Chinese pharmaceutical and biotech companies are leading development of glucagon-like peptide-1 receptor agonists as Novo ...

While Mounjaro has no doubt been a monumental success, Lilly was also working on something else in the background. As Novo Nordisk did, Lilly developed an alternative version of its diabetes drug -- ...

Semaglutide, which is the active ingredient in Novo Nordisk's Wegovy and Ozempic, as well as tirzepatide, are considered GLP-1 drugs. ELI LILLY'S ZEPBOUND REDUCES TYPE 2 DIABETES RISK ...

The Switzerland-based pharmaceutical company has been trying to crack the weight-loss boom currently dominated by Eli Lilly ...